About F-star Therapeutics
f-star is an antibody engineering company focusing on the development and exploitation of technology to generate improved antibodies and antibody derivatives. The company was founded in 2006 and is based in Vienna, Austria.
Missing: F-star Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: F-star Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing F-star Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
F-star Therapeutics is included in 3 Expert Collections, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
F-star Therapeutics Patents
F-star Therapeutics has filed 1 patent.
Clusters of differentiation, Immune system, Immunology, Monoclonal antibodies, Antibodies
Clusters of differentiation, Immune system, Immunology, Monoclonal antibodies, Antibodies
Latest F-star Therapeutics News
Nov 14, 2022
News provided by Share this article Share this article PD-1 and PD-L1 inhibitors clinical trial pipeline constitutes 180+ key companies continuously working towards developing 200+ PD-1 and PD-L1 inhibitors drugs, analyzes DelveInsight LAS VEGAS, Nov. 14, 2022 /PRNewswire/ -- DelveInsight's ' PD-1 and PD-L1 Inhibitors Competitive Landscape – 2022 ' report provides comprehensive global coverage of available, marketed, and pipeline PD-1 and PD-L1 inhibitors drugs in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the PD-1 and PD-L1 inhibitors competitive domain. Key Takeaways from the PD-1 and PD-L1 Inhibitors Pipeline Report Over 180+ PD-1 and PD-L1 inhibitors companies are evaluating 200+ PD-1 and PD-L1 inhibitors pipeline therapies in various stages of development, and their anticipated acceptance in the PD-1 and PD-L1 inhibitors market would significantly increase market revenue. Leading PD-1 and PD-L1 inhibitors companies such as Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene, Apollomics, Agenus, Boehringer Ingelheim, Jounce Therapeutics, Seagen Inc., Ascletis Pharma Inc., Secarna Pharmaceuticals GmbH & Co. KG, Arbutus Biopharma, ABL bio, Macrogenics, AnaptysBio, Avacta, Regeneron Pharmaceuticals, Genor Biopharma Co. Ltd, Genmab, RemeGen, Alphamab, OxSonics therapeutics, Light Chain Bioscience, ImmuneOnco Biopharma, Alpine Immune Sciences, Shanghai Henlius Biotech, Inc., Ocean Biomedical, Akeso Biopharma, Lyvgen Biopharma, Prestige Biopharma, ONO PHARMACEUTICAL CO., LTD., Innovent Biologics, QLSF Biotherapeutics Inc., Servier, Zai Lab, EQRx, Bright Peak Therapeutics, Compass Therapeutics, Inc., Y-Biologics, Shattuck Labs, Beijing Biocytogen, Transcenta Holding, KLUS Pharma Inc., Synermore Biologics, F-Star Therapeutics Inc., Alphamab Oncology, Betta Pharmaceuticals Co., Ltd., Bolt Biotherapeutics, Medicenna Therapeutics, Celldex Therapeutics Inc., TCR² Therapeutics, Transcenta Holding, Merus, SystImmune Inc., TG Therapeutics, Elpiscience, Numab, Janux Therapeutics, Adagene, Molecular Templates, Inc., ImmuneOncia, and others are evaluating novel PD-1 and PD-L1 inhibitors drug candidates to improve the treatment landscape. Key PD-1 and PD-L1 inhibitors pipeline therapies in various stages of development include Envafolimab, Keytruda, FAZ053, TECENTRIQ, Durvalumab, SG 12473, LP 002, HBM 9027, CA 170, Tislelizumab, Geptanolimab, and others. In October 2022, ChemoCentryx, Inc. announced two upcoming poster presentations for CCX559, the Company's investigational, highly potent, orally administered PD-L1 checkpoint inhibitor, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which will be held November 8-12, 2022, in Boston, MA. In October 2022, Compugen Ltd., a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced that it will present new clinical data from its COM701/nivolumab with or without BMS-986207 combination studies in patients with platinum-resistant ovarian cancer, as well as data from the COM701 with or without nivolumab study in patients with metastatic NSCLC, as poster presentations at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) congress taking place between December 7-9, 2022, in Geneva, Switzerland. In October 2022, Imjudo (tremelimumab) from AstraZeneca was approved in the United States in combination with Imfinzi (durvalumab) for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer. In October 2022, GSK announced positive top-line results from the PERLA phase II trial, which met its primary endpoint of objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) criteria as determined by blinded independent central review. In September 2022, Merck announced that KEYTRUDA, Merck's anti-PD-1 therapy, received four new approvals from Japan's Ministry of Health, Labor, and Welfare (MHLW). In July 2022, TRACON Pharmaceuticals, Inc. announced the enrollment of the 36^th patient in the ENVASARC pivotal trial at the 600 mg dose of envafolimab, which enables the initial independent data monitoring committee (IDMC) interim efficacy analysis to proceed. The interim analysis is expected to occur in the fourth quarter of this year. In January 2022, Merck announced that the European Commission had approved KEYTRUDA as monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC) at increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions. Request a sample and discover the recent advances in the PD-1 and PD-L1 inhibitors market @ PD-1 and PD-L1 Inhibitors Competitive Landscape Report PD-1 and PD-L1 Inhibitors Overview Cancer cells have programmed cell death protein 1 (PD-1) on their surfaces. Tumors use it to evade the immune system, so blocking it allows the body to attack and kill cancer. T cells constantly scan our bodies for abnormal cells and eliminate them before they can become cancerous. Finding ways to avoid or shut down the immune system is a critical step in tumor development. PD-1 proteins interact with two ligands, Programmed death-ligand 1 (PD-L1) and Programmed death-ligand 2 (PD-L2). The CD274 gene in humans encodes PD-L1. Some of the FDA-approved PD-1 inhibitor drugs include pembrolizumab (Keytruda), nivolumab (Opdivo), and cemiplimab (Libtayo). These drugs effectively treat various cancers, and new cancer types are added as more research demonstrates their efficacy. PD-L1 inhibitor drugs include atezolizumab (Tecentriq), avelumab (Bavencio), and durvalumab (Imfinzi). Find out more about PD-1 and PD-L1 inhibitors drugs @ FDA-approved PD-1 Inhibitor Drugs PD-1 and PD-L1 Inhibitors Pipeline Analysis: Drug Profile Keytruda: Merck Merck's Keytruda is a humanized monoclonal antibody that binds to the programmed cell death - 1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including anti-tumor immune response. Keytruda has been approved for advanced melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer, classical Hodgkin lymphoma, microsatellite-instability-high cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Renal Cell Carcinoma, Endometrial Carcinoma, and advanced urothelial bladder cancer. FAZ053: Laekna Therapeutics Laekna Therapeutics is developing FAZ053 (anti-PD-L1), an investigational immuno-oncology treatment for patients with advanced cancers. It is a monoclonal antibody that targets the protein programmed cell death-1 ligand 1. (PD-L1). FAZ053, an anti-PD-L1 monoclonal antibody, binds to PD-L1, preventing it from binding to and activating its receptor programmed death 1 (PD-1), potentially enhancing the T-cell-mediated anti-tumor immune response and reversing T-cell inactivation. Laekna intends to begin trials on combination therapies as soon as possible to address unmet cancer needs and bring innovative, effective treatments to more cancer patients in China. A snapshot of the PD-1 and PD-L1 Inhibitors Pipeline Drugs mentioned in the report: Drugs Coverage: Global Key PD-1 and PD-L1 Inhibitors Companies: Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene, Apollomics, Agenus, Boehringer Ingelheim, Jounce Therapeutics, Seagen Inc., Ascletis Pharma Inc., Secarna Pharmaceuticals GmbH & Co. KG, Arbutus Biopharma, ABL bio, Macrogenics, AnaptysBio, Avacta, Regeneron Pharmaceuticals, Genor Biopharma Co. Ltd, Genmab, RemeGen, Alphamab, OxSonics therapeutics, Light Chain Bioscience, ImmuneOnco Biopharma, Alpine Immune Sciences, Shanghai Henlius Biotech, Inc., Ocean Biomedical, Akeso Biopharma, Lyvgen Biopharma, Prestige Biopharma, ONO PHARMACEUTICAL CO., LTD., Innovent Biologics, QLSF Biotherapeutics Inc., Servier, Zai Lab, EQRx, Bright Peak Therapeutics, Compass Therapeutics, Inc., Y-Biologics, Shattuck Labs, Beijing Biocytogen, Transcenta Holding, KLUS Pharma Inc., Synermore Biologics, F-Star Therapeutics Inc., Alphamab Oncology, Betta Pharmaceuticals Co., Ltd., Bolt Biotherapeutics, Medicenna Therapeutics, Celldex Therapeutics Inc., TCR² Therapeutics, Transcenta Holding, Merus, SystImmune Inc., TG Therapeutics, Elpiscience, Numab, Janux Therapeutics, Adagene, Molecular Templates, Inc., ImmuneOncia, and others Key PD-1 and PD-L1 Inhibitors Pipeline Therapies: Envafolimab, Keytruda, FAZ053, TECENTRIQ, Durvalumab, SG 12473, LP 002, HBM 9027, CA 170, Tislelizumab, Geptanolimab, and others. Dive deep for rich insights into PD-1 inhibitors in development; visit @ PD-L1 Inhibitor Drugs Table of Contents PD-1 Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PD-1 non-small cell lung cancer companies, including Wuhan University, Dalian University, MSD, Sichuan University, among others. PD-1 Non-Small Cell Lung Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 non-small cell lung cancer companies, including Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., among others. Other Trending Reports
F-star Therapeutics Web Traffic
F-star Therapeutics Rank
F-star Therapeutics Frequently Asked Questions (FAQ)
When was F-star Therapeutics founded?
F-star Therapeutics was founded in 2006.
Where is F-star Therapeutics's headquarters?
F-star Therapeutics's headquarters is located at Schwarzenbergplatz 7, Vienna.
What is F-star Therapeutics's latest funding round?
F-star Therapeutics's latest funding round is Acq - Pending.
How much did F-star Therapeutics raise?
F-star Therapeutics raised a total of $47.3M.
Who are the investors of F-star Therapeutics?
Investors of F-star Therapeutics include invoX Pharma, Spring Bank Pharmaceuticals, Innovate UK, Atlas Venture, M Ventures and 11 more.
Who are F-star Therapeutics's competitors?
Competitors of F-star Therapeutics include Gliknik, GenScript, Sorrento Therapeutics, HTG Molecular Diagnostics, Fusion Antibodies and 11 more.
Compare F-star Therapeutics to Competitors
Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
Bioventix is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing.
Gliknik is a privately held biopharmaceutical company creating new therapies for patients with cancer and immune disorders. Gliknik specializes in the modulation of the immune system to fight disease. The Gliknik clinical compound is the immune modulator GL-0817 for cancer, which is in a randomized, blinded, placebo-controlled study in the prevention of recurrence of high-risk oral cavity cancer.
Adimab is engaged in the discovery, maturation and production of therapeutic human antibodies. Per the company, Adimab integrates all aspects of antibody discovery and sophisticated screening methods, and therefore can rapidly discover high affinity antibodies that also behave well in a formulation and manufacturing context. The company states that their proprietary library design and presentation technology allows Adimab to discover full-length human antibodies with broad epitope coverage, high affinity and therapeutic relevance faster than any current technology.
NeoClone is a custom monoclonal antibody company focused on developing high quality antibodies for sale as reagents and establishing partnerships and collaborations to develop diagnostic mAbs.
Altus is focused on accelerating the development and commercialization of protein-based products through our Crystalomics technology platform. Crystalomics aims to rapidly turn proteins into products resulting in significant market benefits in Therapeutic, Diagnostic, and Industrial applications.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.